Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
boston blog main
boston top stories
genentech
8
×
life sciences
national blog main
national top stories
new york blog main
8
×
san francisco blog main
new york top stories
san diego blog main
san diego top stories
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
bristol-myers squibb
cancer
celgene
deals
pfizer
eli lilly
fda
ipo
startups
cancer immunotherapy
clinical trials
johnson & johnson
What
bio
roundup
drug
news
approved
big
biotech
cancer
companies
drugs
fda
liver
medical
pharmaceutical
today
acquire
adu
agreed
aiming
alzheimer’s
ambys
annual
appetite
august
beats
bids
billion
biogen
black
bread
breast
broad
busy
butter
buyout
cancer's
cash
clinical
complicated
conference
Language
unset
Current search:
genentech
×
biotech
×
" new york blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine